Canton Strategic Holdings (CNTN) Share-based Compensation (2021 - 2026)
Canton Strategic Holdings posted quarterly Share-based Compensation of $32.3 million for Q1 2026, up 14618.45% year-on-year from N/an in Q1 2025, and up 2586.64% on a QoQ basis from -$1.3 million in Q4 2025.
Canton Strategic Holdings (CNTN) has 6 years of Share-based Compensation data on file, last reported at $32.3 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 14618.45% year-over-year to $32.3 million; the trailing twelve-month figure through Mar 2026 stood at $31.7 million (up 3989.6% YoY), and the FY2025 full-year result was $8253.0, down 98.84% from the prior year.
- Share-based Compensation for Q1 2026 stood at $32.3 million, up from -$1.3 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $32.3 million in Q1 2026 and bottomed at -$1.3 million in Q4 2025.
- The 5-year median for Share-based Compensation is $200000.0 (2025), against an average of $2.0 million.
- The widest annual swing landed in 2022, when Share-based Compensation plunged 7496.83%; it then surged 14618.45% in 2026.
- A 5-year view of Share-based Compensation shows it stood at -$498694.0 in 2022, then jumped by 216.68% to $581862.0 in 2023, then tumbled by 63.72% to $211104.0 in 2024, then tumbled by 714.54% to -$1.3 million in 2025, then surged by 2586.64% to $32.3 million in 2026.
- The last three Share-based Compensation figures came in at $32.3 million (Q1 2026), -$1.3 million (Q4 2025), and $200000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Canton Strategic Holdings | 643.89 Mn | 602.36 Mn | - | 32.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.26 Mn |
| Mar 31, 2026 | 32.26 Mn |
| Dec 31, 2025 | -1.30 Mn |
| Dec 31, 2025 | -1.30 Mn |
| Sep 30, 2025 | 200,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 567,636.00 |
| Jun 30, 2025 | 567,636.00 |
| Mar 31, 2025 | 219,179.00 |
| Mar 31, 2025 | 219,179.00 |
| Dec 31, 2024 | 211,104.00 |
| Dec 31, 2024 | 211,104.00 |
| Sep 30, 2024 | 191,943.00 |
| Sep 30, 2024 | 191,943.00 |
| Jun 30, 2024 | 153,647.00 |
| Jun 30, 2024 | 153,647.00 |
| Mar 31, 2024 | 153,619.00 |
| Mar 31, 2024 | 153,619.00 |
| Dec 31, 2023 | 581,862.00 |
| Dec 31, 2023 | 581,862.00 |
| Sep 30, 2023 | 157,960.00 |
| Sep 30, 2023 | 157,960.00 |
| Jun 30, 2023 | 158,027.00 |
| Jun 30, 2023 | 158,027.00 |
| Mar 31, 2023 | 345,432.00 |
| Mar 31, 2023 | 345,432.00 |
| Dec 31, 2022 | -498,694.00 |
| Dec 31, 2022 | -498,694.00 |
| Sep 30, 2022 | 240,762.00 |
| Sep 30, 2022 | 240,762.00 |
| Jun 30, 2022 | 338,551.00 |
| Jun 30, 2022 | 338,551.00 |
| Mar 31, 2022 | 19,381.00 |
| Mar 31, 2022 | 19,381.00 |
| Dec 31, 2021 | 6,742.00 |
| Dec 31, 2021 | 6,742.00 |
| Sep 30, 2021 | 4,435.00 |
| Sep 30, 2021 | 4,435.00 |
| Jun 30, 2021 | 554,016.00 |
| Jun 30, 2021 | 554,016.00 |
| Mar 31, 2021 | 674,076.00 |
| Mar 31, 2021 | 674,076.00 |